Q-omics provides the consensus-scored CDK8P2 profile across patient tissues and cancer cell-line models. CDK8P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CDK8P2 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, CDK8P2 RNA expression shows 8,543 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight MESO, LUAD, and SARC as cancer lineages where CDK8P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDK8P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDK8P2 survival associations across molecular data types. CDK8P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDK8P2 RNA expression–survival associations across cancer types. High CDK8P2 expression shows unfavorable associations in MESO, ACC, HNSC, KIRC, UCEC and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for CDK8P2 RNA expression.
This table summarizes CDK8P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CDK8P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDK8P2 shows higher tumor expression in LUAD, BLCA, HNSC, KICH, BRCA and COAD. The LUAD box plot shows higher CDK8P2 RNA expression in tumor versus normal tissue (log2 FC = +0.357, t-test p = .001).
This table shows molecular features associated with CDK8P2 in patient tissues and cancer cell lines. In patient samples, CDK8P2 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
